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A B S T R A C T To evaluate the mechanism and role of hyperglucagonemia in the carbohydrate intolerance of uremia, 19 patients with chronic renal failure (12 of whom had undergone chronic hemodialysis for at least 11 mo) and 35 healthy control subjects were studied. Plasma glucagon, glucose, and insulin were measured in the basal state, after glucose ingestion (100 g), after intravenous alanine (0.15 g/kg), and during a 3-h continuous infusion of glucagon (3 ng/kg per min) which in normal subjects, raised plasma glucagon levels into the upper physiological range.
Basal concentrations of plasma glucagon, the increment in glucagon after infusion of alanine, and postglucose glucagon levels were threeto fourfold greater in uremic patients than in controls. The plasma glucagon increments after the infusion of exogenous glucagon were also two-to threefold greater in the uremics. The metabolic clearance rate (MCR) of glucagon in uremics was reduced by 58% as compared to controls. In contrast, the basal systemic delivery rate (BSDR) of glucagon in uremics was not significantly different from controls.
Comparison of dialyzed and undialyzed uremics showed no differences with respect to plasma concentrations, MCR, or BSDR of glucagon. However, during the infusion of glucagon, the increments in plasma glucose in undialyzed uremics were threeto fourfold greater than in dialyzed uremics or controls. When the glucagon infusion rate was increased in controls to 6 ng/kg per min to produce increments in plasma glucagon comparable to uremics, the glycemic response remained approximately twofold greater in the undialyzed uremics. The plasma glucose response to glu-Dr. Felig is the recipient of a Research Career Development Award (AM 70219) from the National Institutes of Health.
Received for publication 2 September 1975 and in revised form 23 October 1975. cagon in the uremics showed a direct linear correlation with oral glucose tolerance which was also improved with dialysis. The glucagon infusion resulted in a 24% reduction in plasma alanine in uremics but had no effect on alanine levels in controls. It is concluded that (a) hyperglucagonemia in uremia is primarily a result of decreased catabolism rather than hypersecretion of this hormone; (b) sensitivity to the hyperglycemic effect of physiological increments in glucagon is increased in undialyzed uremic patients; and (c) dialysis normalizes the glycemic response to glucagon, possibly accounting thereby for improved glucose tolerance despite persistent hyperglucagonemia. These findings thus provide evidence of decreased hormonal catabolism contributing to a hyperglucagonemic state, and of altered tissue sensitivity contributing to the pathophysiological action of this hormone.
INTRODUCTION
Chronic renal failure is characterized by an increased incidence of glucose intolerance (1) (2) (3) . The role of insulin resistance in the pathogenesis of the carbohydrate intolerance in uremia has recently been emphasized (4) . Decreased sensitivity to the hypoglycemic effects of endogenous (2, 5, 6) and exogenous (3, (5) (6) (7) (8) insulin has been observed in uremic man, whereas basal and glucose-stimulated insulin concentrations are normal or increased (1-3, 5, 6, 9) . After chronic dialysis, glucose tolerance generally improves in association with increased tissue sensitivity to insulin (5, (9) (10) (11) (12) (13) . The mechanism of uremia-induced insulin resistance and the improvement in insulin sensitivity after dialysis has not been established. Recently, Bilbrey et al. (14) observed increased levels of circulating glucagon, a known insulin antagonist, in chronic renal failure. The pathophysiological significance of these findings was questioned however, since dialysis resulted in marked im-The Journal of Clinical Investigation Volume 57 March 1976. 722-731 722 provement in glucose tolerance despite unchanged levels of plasma glucagon (14) . The possible role of altered tissue responsiveness to physiological increments of glucagon in uremia and the effect of dialysis on glucagon sensitivity have not been previously examined. Furthermore, whether hyperglucagonemia in uremia is a consequence of increased secretion or is solely due to reduced hormone catabolism has not been determined.
The present study was consequently undertaken to examine the turnover of plasma glucagon and the tissue responsiveness to physiological increments in glucagon in uremia. In the evaluation of glucagon kinetics and sensitivity, special attention was given to the influence of dialysis on these parameters. The data indicate that hyperglucagonemia in uremia is a result of decreased turnover rather than hypersecretion. Furthermore, uremia is associated with increased sensitivity to the hyperglycemic effects of glucagon. This increased tissue sensitivity to glucagon returns to normal after chronic dialysis.
METHODS

Subjects
Two groups of subjects were studied. The control group consisted of 35 healthy, nonobese volunteers (18 males and 17 females) within 15%o of ideal body weight (based on 1959 Metropolitan Life Insurance Company tables). The subjects ranged in age from 18 to 50 yr. They consumed weight-maintaining diets containing at least 200 g of carbohydrate and were taking no drugs. All had negative primary family histories for diabetes mellitus and none had an elevated fasting plasma glucose. 20 of the subjects received an oral glucose tolerance test (100 g) and all demonstrated a normal response (15) .
The uremic group consisted of 19 ambulatory patients (12 males and 7 females) with chronic renal failure, aged 20-63 yr (44+4 yr, mean±-SE). Seven of the patients had not undergone treatment with dialysis before study (undialyzed group). 12 patients had undergone chronic hemodialysis for at least 11 mo in the dialysis unit of the Yale-New Haven Hospital before study. None of the uremic patients had evidence of an acute medical illness or peripheral edema at the time of study. None were receiving corticosteroids. The medications received by dialyzed and undialyzed groups were similar with the exception that 9 of 12 dialyzed subjects and 2 of 7 undialyzed subjects received parenteral androgens. All but three uremic subjects were within 15% of ideal body weight (based on 1959 Metropolitan Life Insurance Company tables). The patients consumed weight-maintaining diets containing at least 250 g of carbohydrate for 3 days before study. Dialyzed patients consumed approximately 80 g of protein, while undialyzed patients were restricted to 50-60 g of protein. Pertinent laboratory data in the uremic group included: serum creatinine, which ranged from 7.5 to 25.1 mg/100 ml (15.6±+1.2, mean+±SE); serum potassium, 4.0-6.9 meq/liter (5.3+0.2, mean+SE); serum bicarbonate, 11.5-25.0 meq/liter (18.6 +1.0, mean+SE); serum calcium, 6.3-10.4 mg/100 ml (8.6 +0.2, mean+SE); and serum phosphate 3.2-14.4 mg/100 ml (6.5+0.6, mean+SE). There were no significant differ-ences with respect to these laboratory values, ages, or weights between the dialyzed and undialyzed patients.
Procedures
All subjects were studied in the postabsorptive state after a 12-15-h overnight fast. Uremic subjects were instructed to omit all medications on the day of study. Dialysis patients were studied just before their next dialysis. An indwelling catheter was inserted in an antecubital vein for blood sampling. An additional catheter was inserted in the contralateral vein or ateriovenous fistula during the glucagon-infusion studies. Subjects were recumbent for at least 20-30 min before study. At least two control blood samples were obtained at 10-15-min intervals before glucose, alanine, or glucagon administration. Control values presented in each study represent the mean of the base-line determinations. Three types of procedures were employed.
Oral glucose tolerance. A 100-g oral glucose tolerance test was performed in 20 normal and 10 uremic subjects. In this study, blood samples were drawn at 30-60-min intervals for 3 h after ingestion of 100 g glucose dissolved in 200 ml of water.
Alanine infusion. L-Alanine (Nutritional Biochemical Corp., Cleveland, Ohio) was given intravenously (0.15 g/kg body weight) over 2-4 min to 21 normal and 9 uremic subjects. Methods used in the preparation of the alanine infusate have previously been described (16) . Blood samples were obtained at 10-30-min intervals for 90 min after the infusion of alanine.
Glucagon infusion. Crystalline beef and pork glucagon (Eli Lilly and Co., Indianapolis, Ind.) was administered as a continuous infusion via a peristaltic pump (Extracorporeal Medical Specialties, Inc., King of Prussia, Pa.) to 21 normal and 10 uremic subjects. Before administration, the glucagon was initially diluted in sterile, pyrogen-free water containing 300 mg/100 ml of human serum albumin (Armour Pharmaceutical Co., Chicago, Ill.). This solution was further diluted with physiological saline and an aliquot of the subject's whole blood (4 ml of whole blood per 100 ml of infusate, to prevent adherence of the glucagon to glassware or tubing) so as to achieve a final glucagon concentration in the infusate of 500 ng/ml. The continuous infusion dose was 3 ng/kg body weight per min, administered for 150-180 min. In eight additional healthy controls, glucagon was infused at a dose of 6 ng/kg body weight per min. Blood samples were obtained at 15-30 min intervals during the infusion.
Analyses and calculations
Glucose was measured by the glucose oxidase technique (17) . The methods employed for the determination of plasma immunoreactive insulin, plasma immunoreactive glucagon (using Unger antibody 30K), and plasma acidic and neutral amino acids have been described previously (18) .
The metabolic clearance rate of glucagon (MCRG),' the volume of plasma completely and irreversibly cleared of glucagon per minute, was calculated according to the formula ( 
RESULTS
Glucagon concentrations in the basal state and after glucose and alanine administration. In accordance with the observations of Bilbrey et al. (14) , the postabsorptive glucagon concentration was increased fourfold in uremic patients (349±32 pg/ml) as compared to controls (90±8 pg/ml, P < 0.001). Basal glucagon levels in uremics were not significantly different in dialyzed (326±34 pg/ml) or undialyzed patients (384±65 pg/ ml). Hyperglucagonemia was also observed in the uremic group after glucose ( Fig. 1 ) or alanine administration ( Fig. 2) . After glucose ingestion, glucagon concentration in the uremics fell by 20-25% below postabsorptive levels; however, the postglucose values in the uremics remained threeto fourfold greater than in the controls (Fig. 1 (21) . Data in of alanine (0.15 g/kg) in normal and uremic subjects. Glucagon levels were significantly greater in the uremic group at 50 min (P <0.02) and at 60 min (P <0.05). No differ-L., R. S. Sherwin, R. Hendler, and P. Felig. ences were noted with respect to dialyzed vs. nondialyzed of glucagon in man: Effects of starvation. In uremics; the data for both uremic groups are consequently combined in the figure. 40±7 pg/ml in controls, P < 0.02). The prolonged elevation of plasma glucagon is compatible with decreased hormone turnover in uremia. The plasma glucagon responses to glucose and alanine administration were not significantly different in the dialyzed as compared to the undialyzed patients.
Glucagon kinetics in uremic and normal subjects.
The continuous infusion of glucagon in the control and uremic patients resulted in stable plasma glucagon concentrations after 15-45 min (Fig. 3 ). However, the increment in glucagon in the uremic group (581±48 pg) was two-to threefold greater than in controls (233 ±13 pg/ml, P < 0.001). Furthermore, the time required to reach a stable plateau after glucagon administration was longer in the uremics (45 min) than in controls (15 min), thus suggesting decreased hormone degradation. The calculated MCRG was 5.8±0.6 ml/kg per min in the uremics, which is 58% below that observed in controls (13.8±0.9 ml/kg per min P <0.001). In After oral glucose administration, the plasma glucose concentration was significantly increased in the uremic group as compared to healthy controls (Fig. 4A) . When uremics were subdivided on the basis of dialysis, undialyzed uremics demonstrated significantly increased glucose values when compared to dialyzed uremics (Fig. 4B) . The improved glucose tolerance in the dialyzed group is also indicated by the fact that the glucose values in this group differed significantly from the control subjects only at 120 and 180 min (P < 0.05) (Fig.  4B ). Plasma insulin concentrations after glucose ingestion closely paralleled the glucose response. Uremic patients demonstrated significantly increased insulin levels when compared to controls (Fig. 4C) . However, whereas the glucose-stimulated insulin response was 2to 10fold above control levels in the undialyzed uremic group throughout the 3-h study, the dialyzed uremics showed only a delayed, 2to 3-fold increment in insulin (Fig.  4D ).
Glucose and insulin responses to intravenous alanine. After alanine administration, the mean maximal increments in glucose and insulin for the uremic group as a whole (7+2 mg/100 and 27+7 AU/ml, respectively), were not significantly different from normal subjects (6±1 mg/100 ml and 15±2 AU/ml, respectively). However, when uremics were subdivided according to dialysis, the mean maximal increments in glucose in the undialvzed uremics (12±3 mg/100 ml) tended to be greater than in controls (6±1 mg/100 ml, P < 0.1) or in dialyzed uremics (3±1 mg/100 ml, P < 0.05). Similarly, the mean maximal increment in insulin in the undialyzed uremics (43±12 ,uU/ml) was significantly greater than in controls (15+2 ,uU/ml, P < 0.05). or in dialyzed uremics (11+2 AU/ml, P < 0.05). Plasma glucose and insulin response to ingestion of 100 g glucose in normal and uremic subjects. In panels A and C, the responses of the dialyzed (n = 6) and undialyzed (n = 4) uremics are combined, while in panels B and D the two uremic groups are shown separately. The glucose response of the undialyzed uremics was significantly greater than the dialyzed group at 60 (P <0.02), 90 (P < 0.01), and 120 min (P < 0.05). Similarly, the insulin response in the undialyzed uremics was greater than in the dialyzed group at 30 (P < 0.02), 60 (P < 0.05), 90 (P < 0.005), 120 (P < 0.005), and 180 min (P < 0.02).
Influence of Uremia and Hemodialysis on Glucagon
Glucose and insulin response to glucagon administration. The increment in plasma glucose concentration after intravenous glucagon infusion was two-to fourfold greater in the uremics as a whole, as compared to controls (Fig. 5A ). However, when the effect of dialysis on glucagon-induced hyperglycemia was examined, the undialyzed uremics account for the differences observed. Despite comparable increments in plasma glucagon in the dialyzed and undialyzed subjects (see above), the glucose response to glucagon was increased above control levels only in the undialyzed uremics (Fig. 5B ). The mean maximal glucose increment in undialyzed uremics (37±9 mg/100 ml) was threeto fourfold greater than in dialyzed uremics (10±1 mg/ 100 ml, P < 0.02) or controls (10±1 mg/100 ml, P < 0.02). Furthermore, the area under the glucoseresponse curve in the undialyzed uremics (2,922+882 mg/100 ml X min) was significantly increased when compared to dialyzed uremics (730±215 mg/100 ml X min, P < 0.05) or controls (577±+150 mg/100 ml X min, P < 0.02). For the entire uremic group, a significant direct linear correlation was observed between the maximal glucose response to glucagon administration and the 2-h plasma glucose concentration during the oral glucose tolerance test (r = 0.82, P < 0.05).
Changes in plasma insulin after glucagon administration were similar to those demonstrated for glucose. Increases in the plasma insulin response to glucagon in uremic subjects were accounted for by hyperinsulinemia in the undialyzed group only (Fig. 5C and D) . Mean maximal insulin increments in undialyzed uremics (27 ±6 ALU/ml) exceeded those of controls (9±1 AU/ml, P < 0.01) and dialyzed uremics (5±1 /LU/ml, P < 0.01).
In addition to the 3 ng/kg per min infusion of glucagon, the healthy control subjects received infusions normal and uremic subjects. In panels A and C, the responses of the dialyzed (n = 5) and undialyzed (n = 5) uremics are combined, while in panels B and D, the two uremic groups are shown separately. The increments in plasma glucose were greater in the undialyzed uremics than in the dialyzed uremics or healthy controls at 45 (P < 0.005), 60 (P < 0.05), 90 (P < 0.05), and 120 min (P < 0.05). Similarly, the insulin response was greater in undialyzed uremics than in dialyzed uremics or normal controls at 45 (P < 0.02), 60 (P < 0.02), 90 (P < 0.01), and 150 min (P < 0.02). at a rate of 6 ng/kg per min. This rate of infusion resulted in increments in plasma glucagon in the normal group which were equivalent to those observed in uremics during the 3 ng/kg per min infusion (Fig. 6 ). Despite comparable hyperglucagonemia, the glucose rise in the undialyzed uremics exceeded that of healthy controls (Fig. 6 ). The mean maximal glucose increment in the control subjects receiving the 6 ng/kg per min glucagon infusion (16±3 mg/100 ml) was less than half that observed in the undialyzed uremic group receiving the 3 ng/kg per min infusion (37±9 mg/100 ml, P < 0.05). The maximal insulin increment in the controls during the 6 ng/kg per min infusion (12+3 /LU/ml) was significantly below that observed in the undialyzed uremics during the 3 ng/kg per min infusion (27±6, P < 0.05).
Plasma amino acids in the basal state and after glucagon administration. Plasma amino acid concentrations in the basal state and the changes observed after glucagon infusion are shown in Table I . Uremic subjects demonstrated threefold increases in basal levels of citrulline and cystine (P < 0.001), as well as elevated taurine (P < 0.05), glycine (P < 0.01), and proline (P < 0.001) concentrations. Basal valine (P < 0.005), tyrosine (P < 0.02), and a-aminobutyrate (P < 0.05) concentrations were significantly reduced. No differences were observed between dialyzed and undialyzed subjects except in the case of glycine. Glycine concentration in the dialyzed group (548+90 umol/liter) was twice that observed in the undialyzed group (249±+18, P < 0.01) or in normal controls (207±16, P < 0.005). Changes in plasma glucagon and glucose in undialyzed uremics and in normal controls during the infusion of glucagon at rates causing equivalent increases in plasma glucagon. Glucagon was infused at a rate of 3 ng/kg per min in the uremics (n = 5) and at a rate of 6 ng/kg per min in the normal controls (n = 8). The glucose response over the course of the study was significantly greater in the uremics as compared to controls (P <0.02, analysis of variance). In addition, the mean maximal increment in glucose in the uremics (37±9 mg/100 ml) was significantly greater than in controls (16±3 mg/100 ml, P < 0.05).
The glucagon infusion (3 ng/kg per min) failed to produce any consistent changes in plasma amino acid concentrations in the normal control group, except for a 7% decline in serine (Table I) . In contrast, a significant fall in virtually all amino acids was demonstrable in the uremic group (Table I) . The magnitude of the decrease in alanine (24±2%) exceeded that of all other amino acids. The amino acid response to glucagon was the same in dialyzed and undialyzed uremic patients. When the glucagon infusion rate was increased to 6 ng/kg per min in normals to achieve increments in plasma glucagon comparable to the uremics (Fig. 6) , plasma alanine concentration still failed to decline in the normal group (Fig. 7) . With the exception of small (10-19%) reductions in glycine, serine, and threonine, the other amino acids were also unchanged by the high-dose glucagon infusion.
DISCUSSION
The current data demonstrate that chronic renal failure is associated with hyperglucagonemia in the basal state, after glucose suppression, and after alanine stimulation. Similar results have been previously reported with respect to basal and postglucose values (14) . Bilbrey et al., however, failed to observe augmented glucagon levels after protein ingestion (14) . Whether the differences observed between protein ingestion and intravenous alanine are related to altered protein absorption in uremia (22) , or are due to the different nature of the aminogenic stimulus remains to be determined. The present findings extend previous observations, (a) by providing data on the relative contributions of altered hormone catabolism and secretion to increased plasma glucagon levels in uremia, and (b) by evaluating the effects of uremia and dialysis on the glycemic and amino acid responses to physiological increments in plasma glucagon.
In the uremic group, the MCRG was decreased by 58% as compared to healthy subjects. In contrast, the BSDRG was unchanged from controls. These data thus suggest that hyperglucagonemia in uremia is a consequence of decreased hormonal catabolism rather than hypersecretion. The techniques employed in the current study cannot exclude the possibility of increased hepatic extraction of glucagon and associated hypersecretion in the uremic group. However, previous observations in intact man have demonstrated a portal-peripheral gradient for glucagon which is no greater than 1.3: 1, indicating that the liver is a minor site of glucagon degradation (23) . Thus, the comparable BSDRG in the uremic and normal subjects are likely to be a close approximation of the true pancreatic secretory rates. It should be noted that the calculations employed in determining MCRG assume ongoing secretion of en- as mean ±SE. P values refer to significance of difference from preinfusion values I Indicates that amino acids were measured at 150 min in uremics and 180 min in normal subjects. § Indicates normal subjects (n = 10). 1 1 Indicates uremic subjects (n = 10).
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Indicates P < 0.05. ** Indicates P < 0.01. $1 Indicates P < 0.001. dogenous glucagon. This assumption is based on indirect evidence in normal subjects infused with glucagon followed by glucose (20) . If this assumption were not valid, the values for MCRa would be lower both in the controls (9.5+0.4 ml/kg per min) and the uremics (3.6±0.4). However, the significant differences between these groups (P < 0.001) would not be appreciably altered. On the other hand, if one assumes that endogenous glucagon secretion is suppressed in controls but not in uremics, the metabolic clearance rate in the uremics remains significantly reduced when compared to controls (P < 0.001).
The demonstration that hyperglucagonemia in uremia is associated with decreased hormonal catabolism strongly implicates the kidney as a principal site of glucagon degradation. As noted above, the small portal-728 Sherwin, Bastl, Finkelstein, Fisher, Black, Hendler, and Felig FIGURE 7 Changes in plasma alanine in r4 infusion of glucagon in uremic and normal normal subjects were studied during the inft gon at rates of 3 and 6 ng/kg per min. Thei the uremics was 3 ng/kg per min. The alani dialyzed and undialyzed uremics was the sam the data for the two uremic groups are co figure. P values refer to the significance c from the basal concentration. In the norma both infusion rates) there were no significa alanine levels during the infusion.
peripheral gradient for glucagon (23, 24) with an extrahepatic degradative site. Glu dative enzymes have, in fact, recently been in kidney tissue (25) . Consistent renal glucagon has been observed in the autotrac kidney (26) . Recent studies in our labora' fractional extraction ratio of glucagon acro in the intact dog and rat of 40%.3 After the renal failure by 75% nephrectomy, a consist take of glucagon is no longer observed.3 renal artery clamping (27) and ureteral lig dogs result in a rapid rise in plasma gluca trast, a decrease in circulating glucagon after successful renal transplantation in These data thus indicate that renal funct taken into account in interpreting plasr levels in a variety of pathological states. gonemia associated with traumatic shock myocardial infarction (30) , diabetic ketoae and hyperosmolar coma (32) (Fig. 5 ). Furthermore, when the glucagon infusion rate was increased in normals (6 ng/kg per min) so as to achieve increments in plasma glucagon comparable to the uremics, the glucose response remained two-to threefold greater in the undialyzed uremics (Fig. 6 ). In addition to the response to exogenous glucagon, the glycemic response to alanine-stimulated secretion of endogenous glucagon was also greater in undialyzed uremics than in controls or dialyzed uremics. These data thus suggest that uremia is characterized by increased sensitivity to the 150 80 hyperglycemic effects of physiological increments in glucagon. This augmented sensitivity to glucagon reesponse to the turns to normal after dialysis.
subjects. The The importance of altered tissue responsiveness to ision of gluca-glucagon in uremia is underscored by the differential infusion rate in effects of dialysis on glucose tolerance and plasma glune response in e consequently cagon levels. Although, in according with previous mbined in the reports (5, (9) (10) (11) (12) , dialysis was associated with an imf the changes provement in glucose tolerance (Fig. 4) , plasma glu-L1 subjects (at cagon levels remained unchanged. On the other hand, .nt changes in a direct linear correlation was observed between the 2-h plasma glucose response to glucose ingestion and the is compatible glycemic response to glucagon infusion. These observacagon degra-tions suggest that increased tissue sensitivity to the demonstrated glycemic effects of glucagon is an important factor in extraction of uremia-induced glucose intolerance. Improvement in asplanted dog glucose tolerance after chronic dialysis is associated tory reveal a with a return of glucagon sensitivity to normal. It tss the kidney should be noted that previous studies involving bolus induction of injections of 0.15-1.0 mg of glucagon have shown a tent renal up-variable glucose response to glucagon in uremic pa-Furthermore, tients (1, 2, 5, 33) . However, the data on the BSDRG ation (14) in glucagon (less than 2 ng/kg per min in both the Lgon. In con-uremics and controls) indicate that such bolus injecis observed tions represent pharmacological rather than physiologiman (28) . cal doses of glucagon.
tion must be Regarding the mechanism of augmented glucagon na glucagon sensitivity in uremia, recent studies have demonstrated Hypergluca-increased sensitivity to glucagon-induced hyperglycemia (29) , acute in circumstances of acute insulin deficiency (34) and cidosis (31), in insulin-withdrawn diabetics (20) . On the other hand, be explained physiological increments in glucagon do not alter glu-I with these cose tolerance in normal subjects, chemical diabetics, or in juvenile-onset diabetics receiving insulin (20) . F uremia and The current findings of hyperinsulinemia in the undianous and enlyzed uremics (Fig. 5 ) indicate that hypersensitivity to xinkelstein, J. glucagon in uremia cannot be ascribed to insulin deficiency. The insulin response to oral glucose (Fig. 4 ), intravenous alanine, and exogenous glucagon ( Fig. 5 ) was increased in the undialyzed uremics, yet was associated with a deterioration in glucose tolerance, suggesting insulin resistance. Whether insulin resistance is a cause or a consequence of augmented tissue responsiveness to glucagon in undialyzed uremics remains to be determined. The current data do not exclude the possibility that uremia results in alterations in hepatic glucagon receptors or in steps subsequent to receptor binding, independent of altered tissue responsiveness to insulin.
Regarding amino acid concentrations in uremia, in accordance wvith previous observations (22, (35) (36) (37) , uremic subjects demonstrated increases in plasma, glycine, cystine, citrulline, proline, and taurine, and decreases in tyrosine, valine, and a-aminobutyrate. The amino acid pattern in uremia differed from prolonged starvation in which circumstance hypoalaninemia is a striking find (38) , thus it suggests that the alterations observed in uremia are not primarily the result of caloric deprivation. While increased glycine and proline levels are seen in protein malnutrition (39, 40) , the threefold increases in citrulline and cystine in uremic subjects are not observed in protein deficiency (39, 40) . Furthermore, dialyzed uremics were maintained on a diet of normal protein content (80 g). These data suggest that nondietary factors contribute to the changes observed in amino acids in uremia. The increased citrulline concentration may reflect alterations in urea cycle activity; elevated arginine levels have also been observed in uremic patients (22, (35) (36) (37) . Particularly noteworthy are the normal levels of serine in the uremic group (Table I) . Studies in normal subjects have shown that the kidney is the principal source of plasma serine which is extracted by the liver as well as muscle (41) . The failure to observe a fall in serine in uremics suggests either a compensatory reduction in extrarenal uptake, stimulation of extrarenal production, or residual renal release in the uremic group.
Although the infusion of glucagon in the normal subjects failed to alter plasma amino acid levels, the uremics demonstrated reductions in virtually all amino acids (Table I ). The glucagon-induced reduction in plasma alanine in the uremic patients exceeded that of all other amino acids. These results suggest increased sensitivity to the gluconeogenic effects of glucagon in uremia. Increased amino acid incorporation into glucose has been observed in perfused rat livers after nephrectomy (42) . It should be noted that while dialysis normalized the glucose response to glucagon (Fig. 5 ), the hypoalaninemic response to glucagon was comparable in dialyzed and nondialyzed patients. These observations suggest that the glycogenolytic and gluconeogenic responses to glucagon may be independently influenced by the uremic state.
